hier.
Transcrição
hier.
Prof. Dr. med. Eckhart Weidmann Literaturverzeichnis Bergmann L, Mitrou PS, Demmer-Dieckmann M, Ruhmann FT, Weidmann E: Impaired T- and B cell function in Hodgkin's disease. Reduced mitogenic responsibility and IL-2 production is not caused by defective CD4+ cells. Cancer Immunol Immunother 25 (1987) 59-64. Bergmann L, Mitrou PS, Weidmann E, Schmidt-Matthiesen A, Hanke P, Hoelzer D: In vitro and in vivo induction of lymphokine activated killer cells (LAK cells) in patients with gastric cancer and other malignant diseases. In Koldovsky et al. (eds.): Lymphocytes in immunotherapy of cancer: Springer Verlag, Berlin, New York (1989) 32-40. Bergmann L, Weidmann E, Bungert B, Hechler P, Mitrou PS: Influence of various cytokines on the induction of lymphokine activated killer cells. Nat Immun Cell Growth Regul 9 (1990) 265-273. Bergmann L, Weidmann E, Mitrou PS, Runne U, Keilholz U, Bartsch HH, Franks CR: Interleukin 2 in combination with Interferon- in disseminated malignant melanoma and renal cell carcinoma. A phase I/II study. Onkologie 13 (1990) 137-140. Bergmann L, Weidmann E, Mitrou PS: Immuntherapie des fortgeschrittenen Nierenzellkarzinoms. Dtsch Med Wschr 116 (1991) 384-390. Weidmann E, Bergmann L, Hechler P, Mitrou PS: Cytotoxic activity and phenotypic characteristics of lymphocyte subsets after therapy of cancer with interleukin 2. Cancer Immunol Immunother 33 (1991) 398-402. Bergmann L, Weidmann E, Enzinger HM, Fenchel K, Jonas D, Mitrou PS: Interleukin 2 and interferon-alpha as a daily alternating schedule in advanced renal cell cancer. Preliminary results of a phase II study. World J Urol 9 (1991) 215-218. Shimizu Y, Weidmann E, Iwatsuki S, Herberman RB, Whiteside TL: Characterization of human autotumor-reactive T cell clones obtained from tumor infiltrating lymphocytes in liver metastasis of gastric carcinoma. Cancer Res 51 (1991) 6153-6162. Weidmann E, Bergmann L, Stock J, Kirsten R, Mitrou PS: Rapid cytokine release in cancer patients treated with Interleukin 2. J Immunother. 12 (1992) 123-131. Weidmann E, Whiteside TL, Giorda R, Herbermann RB, Trucco M: The T cell receptor Vß usage in tumor infiltrating lymphocytes and blood of patients with hepatocellular carcinoma. Cancer Res 52 (1992) 5913-5920. Weidmann E, Sacchi M, Plaisance S, Heo DS, Yasumura S, Lin W, Johnson JT, Herberman RB, Azzarone B, Whiteside TL: Receptors for interleukin 2 (IL2R) on human squamous cell carcinoma cell lines and tumor in situ. Cancer Res 52 (1992) 5963-5970. Weidmann E, Bergmann L, Hechler P, Schwulera U, Grieser H, Mitrou PS: Interleukin 2 in the treatment of cancer disease: Introduction af a therapeutic model and some immunological data. In Fleischer (ed.): Leukemia. Springer-Verlag Heidelberg, Berlin (1993) 111-116. Bergmann L, Fenchel K, Weidmann E, Enzinger HM, Jahn B, Jonas D, Mitrou PS: Daily alternating administration of high dose interferon- and interleukin 2 bolus infusion in metastatic renal cell cancer. A phasa II study. Cancer 72 (1993) 1733-1742. Keilholz U, Schreibenbogen C, Tilgen W, Bergmann L, Weidmann E, Seither E, Richter M, Brado B, Mitrou PS, Hunstein W: Interferon- and interleukin 2 in the treatment of metastatic melanoma: Comparison of two phase II trials. Cancer 72 (1993) 607-614. Weidmann E, Elder EM, Trucco M, Lotze MT, Whiteside TL: Usage of the T cell receptor beta chain genes in fresh and cultured tumor infiltrating lymphocytes from human melanoma. Int J Cancer 54 (1993) 383-390. Weidmann E, Logan TF, Yasumura S, Kirkwood JM, Trucco M, Whiteside TL: Evidence for oligoclonal T cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro sensitized vaccine draining lymph node lymphocytes. Cancer Res 53 (1993) 4745-4749. Weidmann E, Elder EM, Herberman RB, Trucco M, Whiteside TL: The T cell receptor beta chain variable region repertoire in fresh and cultured lymphocytes isolated from malignant melanoma. In Bergmann L, Mitrou PS (eds.): Contributions to oncology: Cytokines in cancer therapy. Karger Verlag, Basel 46 (1994) 133-142. Keilholz U, Schreibenbogen C, MacLachlan D, Jochim A, Bergmann L, Weidmann E,Mitrou PS, Tilgen W, Hunstein W: Treatment of malignant melanoma with interferon alpha and high dose interleukin 2. In Bergmann L, Mitrou PS (eds.): Contributions to oncology: Cytokines in cancer therapy. Karger Verlag, Basel 46 (1994) 191-198. Weidmann E, Trucco M, Whiteside TL: Relevance of the T cell receptor for immunotherapy of cancer. Cancer Immunol Immunother 39 (1994) 1-14. Conrad B, Weidmann E, Trucco G, Rudert WA, Behboo R, Ricordi C, Rodrigues Rilo H, Feingold D, Trucco M: Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. Nature 371 (1994) 351-355. Yasumura S, Weidmann E, Hirabayashi H, Johnson JT, Herberman RB, Whiteside TL: HLA restriction and T cell receptor Vß gene expression of cytotoxic T lymphocytes reactive with human squamous cell carcinoma of the head and neck. Int J Cancer 57 (1994) 297-305. Yasumura S, Lin WC, Weidmann E, Hebda P, Whiteside TL: Expression of interleukin 2 receptors on human carcinoma cell lines and tumor growth inhibition by interleukin 2. Int J Cancer 59 (1994) 225-234. Brieger J, Weidmann E, Fenchel K, Mitrou PS, Hoelzer D, Bergmann L: The expression of the Wilms tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia 8 (1994) 2138-2143. Jahn B, Bergmann L, Weidmann E, Brieger J, Fenchel K, Schwulera U, Hoelzer D, Mitrou PS: Bone marrow derived T cell clones of previously untreated acute myelocitic leukemia with blast directed autologous cytotoxicity. Leukemia Res 19 (1995) 73-82. Weidmann E, Brieger J, Jahn B, Hoelzer D, Bergmann L, Mitrou PS: Lactate dehydrogenase release assay. A reliable, non-radioactive technique for analysis of cytotoxic lymphocyte mediated lytic activity against blasts from acute myelocytic leukemia. Ann Hematol 70 (1995) 153-158. Weidmann E, Brieger J, Bergmann L, Hoelzer D, Mitrou PS: AML blasts variably express interleukin 2 receptor or chains without measurable effects on proliferation, cytokine message expression or surface expression of adhesion molecules upon stimulation with interleukin 2. Leukemia Res 19 (1995) 469-476. Brieger J, Weidmann E, Maurer U, Hoelzer D, Mitrou PS, Bergmann L: The Wilms` tumor gene is frequently expressed in acute myeloblastic leukemias and may provide a marker for residual blast cells detectable by PCR. Ann Oncol 6 (1995) 811-816. Bergmann L, Schui DK, Brieger J, Weidmann E, Mitrou PS, Hoelzer D: The inhibition of ymphokine-activated killer cells is mediated by transforming growth factor-1. Exp Hematol 23 (1995) 1574-1580. Weidmann E, Brieger J, Fenchel K, Hoelzer D, Bergmann L, Mitrou PS: IL-2 receptor alpha, beta and gamma chains expressed on blasts of acute myelocytic leukemia may not be functional. Acute Leukemias V. Experimental approaches and management of refractory diseases. Hiddemann et al., (Eds.) (1996) 542-546. Brieger J, Weidmann E, Fenchel K, Mitrou PS, Bergmann L, Hoelzer D: The amplification of the Wilms tumor gene (wt-1) mRNA using the polymerase chain reaction technique (PCR) may enable sensitive detection of small blast populations in AML. Acute Leukemias V. Experimental approaches and management of refractory diseases. Hiddemann et al., (Eds.) (1996) 501-505. Schui DK, Brieger J, Weidmann E, Mitrou PS, Hoelzer D, Bergmann L: The inhibition of lymphokine-activated killer cell activation mediated by AML culture supernatants might be due to transforming growth factor beta 1. Acute Leukemias V. Experimental approaches and management of refractory diseases. Hiddemann et al., (Eds.) (1996) 294-297. Weidmann E: Gentransfer als neues Therapieprinzip hämato-onkologischer Neoplasien. In: Zytokine (Niederle, Bergmann, Ganser, eds.) Fischer Verlag, Jena (1996) 238-250. Karakas T, Bergmann L, Stutte HJ, Jäger E, Knuth A, Weidmann E, Mitrou PS, Hoelzer D: Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas. Leukemia and lymphoma 24 (1996) 121-129. Brieger J, Weidmann E, Maurer U, Mitrou PS, Hoelzer D, Bergmann L: Detection of the Wilms’ tumor gene (wt-1) mRNA in complete remission of AML frequently precedes relapse. Acute Leukemias VI. Prognostic factors and tratment strategies. Büchner T. et al., (Eds.) (1997) 120-124. Weidmann E, Brieger J, Karakas T, Maurer U, Hoelzer D, Mitrou PS, Bergmann L: Establishment and characterization of a new, factor independent FAB M2 acute myeloid leukemia line, Ei501. Leukemia 11 (1997) 709-713. Bergmann L, Maurer U, Weidmann E: Wilms’ tumor gene expression in acute myeloid leukemias. Leukemia & Lymphoma 25 (1997) 435-443. Maurer U, Brieger J, Weidmann E, Mitrou PS, Hoelzer D, Bergmann L: The Wilms’ tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in course of differentiation in vitro. Exp Hematol 25 (1997) 945-950. Begmann L, Miething CC, Maurer U, Brieger J, Karakas T, Weidmann E, Hoelzer D: High levels of Wilms’ tumor gene (wt1) RNA in acute myeloid leukemias are associated with a worse long term outcome. Blood 90 (1997) 1217-1225. Maurer U, Weidmann E, Karakas T, Hoelzer D, Bergmann L: Wilms tumor gene (wt1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34 + Progenitors. Blood [letter] 90 (1997) 4230-4231. Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L: High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol 9 (1998)159-165. Raab C, Weidmann E, Schmidt A, Bergmann L, Badenhoop K, Usadel K-H, Haak T: The effects of interleukin 2 treatment on endothekin and the activation of the hypothalamic-pituitary-adrenal axis. Clin Endocrinol 50 (1999) 37-44. Klein SA, Ottmann OG, Ballas K, Dobmeyer TS, Pape M, Weidmann E, Hoelzer D, Kalina U: Quantification of human interleukin 18 mRNA expression by competitive reverse transcriptase polymerase chain reaction. Cytokine 11 (1999) 451-458. Weidmann E, Baican B, Hertel A, Baum RP, Chow KU, Knupp B, Adams S, Hör G, Hoelzer D, Mitrou PS: Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin’s disease. Leukemia & Lymphoma, 34 (1999) 545-551. Staszewski S, Miller V, Sabin C, Carlebach A, Berger A-B, Weidmann E, Helm EB, Hill A, Phillips A: Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS 13 (1999) 367-373. Staszewski S, Miller V, Sabin C, Schlecht C, Gute P, Stamm S, Leder T, Berger A, Weidmann E, Hill A, Phillips A: Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS 13 (1999), 951-956. Miller V, Staszewski S, Sabine C, Carlebach A, Rottmann C, Weidmann E, Rabenau H, Hill A, Cozzi Lepri A, Phillips AN: CD4 lymphocyte count as a predictor of the duration of HAART-induced suppression of HIV-1 virus load. J Infect Disease 180 (1999) 530-533. Chow KU, Rummel MJ, Weidmann E, Ries J, Jantschke P, Boehrer S, Pourebrahim F, Martin H, Stein J, Hoelzer D, Mitrou PS: Induction of apoptosis by 2-chloro-2’deoxyadenosine (2-CdA) alone and in combination with other cytotoxic drugs. Synergistic effects on normal and neoplastic lymphocytes by addition of doxorubicine and mitoxantrone. Leukemia and Lymphoma 36 (2000) 559-567. Chow KU, Ries J, Weidmann E, Pourebrahim F, Napieralski S, Stieler M, Boehrer S, Rummel MJ, Stein J, Hoelzer D, Mitrou PS: Induction of apoptosis by 2’,2’ difluorodeoxycytidine (gemcitabine) in combination with antimetabolites or anthracyclins on malignant lymphatic and myeloid cells. Antagonism or synergism depends on incubation schedule and origin of neoplastic cells. Ann Hematol 79 (2000) 485-492. Weidmann E: Hepatosplenic T-cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 14 (2000) 991-997. Viertel A, Weidmann E, Ditting T, Geiger H: Management of renal complications in patients with advanced multiple myeloma. Leuk Lymphoma 38 (2000) 513-519. Viertel A, Weidmann E, Wigand R, Geiger H, Mondorf UF: Treatment of severe systemic lupus erythematodes with immunoadsorption and intravenous immunoglobulins. Intens Care Med 26 (2000) 823-824 [letter]. Viertel A, Weidmann E, Rickerts V, Scheuermann EH, Geiger H, Brodt HR: Renal involvement in HIV infection. A review and a retrospective analysis of the Frankfurt AIDS cohort study. Eur J Med Res 5 (2000) 185-198. Weidmann E, Hinz T, Klein SA, Schui DK, Harder S, Kriener S, Kabelitz D, Hoelzer D, Mitrou PS: Cytotoxic Hepatosplenic T-Cell Lymphoma Following Acute Myeloid Leukemia Bearing Two Distinct Chains of the T-Cell Receptor. Biologic and Clinical Features. Haematologica 85 (2000) 1024-1031. Miller V, Sabin CA, Phillips AN, Rottmann C, Rabenau H, Weidmann E, Rickerts V, Findhammer S, Helm EB, Staszewski S: The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and ist relationship to CD4 and viral load. AIDS 14 (2000) 2129-2136. Miller V, Sabin C, Hertogs K, Bloor S, Martinez-Picado J, D’Aquila R. Larder B, Lutz T, Gute P, Weidmann E, Rabenau H, Phillips A, Staszewski S: Virological and immunological effects of treatment interuptions in HIV-1 infected patients with treatment failure. AIDS 14 (2000) 2857-2867. Chow KU, Schneider B, Mitrou PS, Weidmann E: Influence of various cytokines on the expression of CD20 on the surface of CLL-cells in vitro. Leuk Res 25 (2001) 99-100. Maurer U, Jehan F, Englert C, Hubinger G, Weidmann E, DeLuca HF, Bergmann L: The Wilms’ tumor gene product (Wt1) modulates the response to 1,25-dihydroxyvitamin D3 by induction of the vitamin D-receptor (VDR). J Biol Chem 276 (2001) 3727-3732. Boehrer S, Hinz T, Schui DK, Harder S, Chow KU, Schneider B, Hoelzer D, Mitrou P.S., Weidmann E: T-large granular lymphocyte leukemia with natural killer-cell-like cytotoxicity and expression of two different and TCR chains. Br J Haematol 112 (2001) 201-203. Fauth F, Weidmann E, Martin H, Schneider B, Sonnhoff S, Hoelzer D. AC133 expression on acute myeloid leukemia blasts: correlation to FAB and to CD34 expression and possible implications for peripheral blood progenitor cell purging in AML, Leukemia Res 25 (2001) 191-196. Boehrer S, Chow KU, Puccetti E, Ruthardt M, Godhzisard S, Krahpohl A, Schneider B, Hoelzer D, Mitrou PS, Rangnekar VM, Weidmann E: Deregulated expression of prostate apoptosis response gene-4 (PAR-4) in less differentiated lymphocytes and mutually exclusive patterns of Par-4 and Bcl-2 in acute lymphocytic leukemia. Hematol J 2 (2001) 103-107. Weidmann E, Boehrer S, Chow KU, Engels K, Harder L, Hinz T, Janssen O, Kriener S, Rummel MJ, Siebert R, Kabelitz D, Hansmann ML, Hoelzer D, Mitrou PS: Treatment of Aggressive and Progressing Indolent Peripheral T- and NK- Cell Neoplasias by Combination of Fludarabine, Cyclophosphamide and Doxorubicine Introduction of a Protocol by the „Study Group Peripheral T- and NK-Cell Neoplasias“. Onkologie 24 (2001) 162-164. Chow KU, Boehrer S, Geduldig K, Krapohl A, Hoelzer D, Mitrou PS, Weidmann E: In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin’s lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica 86 (2001) 485-493. Mahlknecht U, Weidmann E, Seipelt G: Black tea delays recovery from iron deficiency anaemia. Haematologica (2001) 559. Hinz T, Weidmann E, Kabelitz D: Dual TCR-expressing T lymphocytes in health and disease. Int Arch Allergy Immunol 125 (2001) 16-20. Viertel A, Weidmann E, Brodt H-R: Akute Vergiftungen in der Internistischen Intensivmedizin. Dtsch Med Wochenschr 126 (2001) 1159-1163. Weidmann E: Differenzierung der Lymphozyten. In: Non-Hodgkin-Lymphome. Mitrou PS (Ed.) Tumorzentrum Rhein/Main Selbstverlag (2001) 3-14. Weidmann E: Molekularbiologische Grundlagen. In: Non-Hodgkin-Lymphome. Mitrou PS (Ed.) Tumorzentrum Rhein/Main Selbstverlag (2001) 15-22. Weidmann E, Engels K, Fellbaum C: Immunologische Typisierung von Lymphomen und Leukämien. In: NonHodgkin-Lymphome. Mitrou PS (Ed.) Tumorzentrum Rhein/Main Selbstverlag (2001) 25-34. Weidmann E, Fellbaum C, Mitrou PS: Hochmaligne B-Zell Lymphome. In: Non-Hodgkin-Lymphome. Mitrou PS (Ed.) Tumorzentrum Rhein/Main Selbstverlag (2001) 163-181. Weidmann E, Mitrou P.S., Fellbaum C: Lymphome und Leukämien der T-Zellreihe In: Non-HodgkinLymphome. Mitrou PS (Ed.) Tumorzentrum Rhein/Main Selbstverlag (2001) 221-234. Chow KU, Sommerlad D, Boehrer S, Schneider B, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E: AntiCD20 antibody (IDEC-C2B8, Rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement and caspases. Haematologica 87 (2002) 33-43. Mitrou PS, Weidmann E, Rummel M: Non-Hodgkin-Lymphome (NHL). Teil I: Grundlagen, Lymphozytendifferenzierung, Klassifikation, Diagnostik, Stadieneinteilung, Zytogenetik der NHL. Arztneimitteltherapie 20 (2002) 14-23. Chow KU, Boehrer S, Bojunga J, Stieler M, Rummel MJ, Fauth F, Schneider B, Martin H, Hoelzer D, Weidmann E, Mitrou PS: Induction of apoptosis by cladribine, gemcitabine and other chemotherapeutic drugs on CD34+/CD38+ and Cd34+/CD38- hematopoietic progenitor cells. Selective Effects by doxorubicin and cladribine with protection of immature cells. Leuk & Lymphoma 43 (2002) 377-384. Mitrou PS, Weidmann E, Rummel M: Non-Hodgkin-Lymphome. Teil III: Hochmaligne Lymphome und HIVassoziierte, primär extranodale Lymphome der B-Zell-Reihe. Arztneimitteltherapie 20 (2002) 105-115. Mitrou PS, Weidmann E, Rummel M: Non-Hodgkin-Lymphome. Teil IV: Periphere Lymphome der TZellreihe, primäre kutane Lymphome. Arztneimitteltherapie, 20 (2002) 152-162. Schui DK, Singh L, Schneider B, Krapohl A, Hoelzer D, Weidmann E: Inhibiting effects on the induction of cytotoxic T-lymphocytes by dendritic cells pulsed with lysates from AML blasts. Leuk Res 26 (2002) 383-389. Boehrer S, Chow KU, Beske F, Kukoc-Zivojnov N, Puccetti E, Ruthardt M, Baum C, Rangnekar VM, Hoelzer D, Mitrou PS, Weidmann E: In lymphatic cells Par-4 sensitizes to apoptosis by down-regulating Bcl-2 and promoting disruption of mitochondrial membrane potential and caspase activation. Cancer Res 62 (2002) 17681775. Karakas T, Miething CC, Maurer U, Weidmann E, Ackermann H, Hoelzer D, Bergmann L: The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in acute myeloid leukemia. Leukemia 16 (2002) 846-854. Boehrer S, Chow KU, Ruthardt M, Hoelzer D, Mitrou PS, Weidmann E: Expression and function of prostateapoptosis-response-gene-4 in lymphatic cells. Leuk Lymphoma 43 (2002) 1737-1741. Rummel MJ, Chow KU, Hoelzer D, Mitrou PS, Weidmann E: In vitro studies with bendamustine: Enhanced activity in combination with rituximab. Semin Oncol 29 (2002; suppl. 13) 12-14. Weidmann E, Kim S-Z, Rost A, Seiperlt G, Hoelzer D, Mitrou PS: Bendamustin is effective in relapsed or refractory high-grade non-Hodgkin’s lymphoma. Ann Oncol 13 (2002) 1285-1289. Boehrer S, Schui DK, Chow KU, Hoelzer D, Mitrou PS, Weidmann E: Cytotoxic activity of T- and NK-cell lymphoma cells is not dependent on an mature cytotoxic phenotype. Leuk Lymphoma 43 (2002) 2363-2368. Chow KU, Boehrer S, Napieralski S, Nowak D, Knau A, Hoelzer D, Mitrou PS, Weidmann E: In AML cell lines ara-c combined with purine analogues is able to exert synergistic as well as antagonistic effects on proliferation, apoptosis, and disruption of mitochondrial membrane potential. Leuk Lymphpoma 44 (2003) 165173. Chow KU, Nowak D, Boehrer S, Ruthard M, Knau A, Hoelzer D, Mitrou PS, Weidmann E: Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol 66 (2003) 711-724. Kim, SZ, Zollner TM, Schui DK, Chow KU, Sterry W, Kriener S, Hoelzer D, Mitrou PS, Weidmann E: CD4+/CD56+ neoplasia. Clinical features with emphasis on cytotoxic drug-induced apoptosis and expression of sialyl Lewis X. Leuk Lymphoma 44 (2003) 281-289. Weidmann E, Gramatzki M, Wilhelm M, Mitrou PS: Diagnosis and actual therapy strategies in peripheral Tcell lymphomas – summary of an international meeting. Ann Oncol 15 (2004) 369-374. Boehrer S, Brieger A, Schaaf S, Kukoc-Zivojnov N, Nowak D, Ruthardt M, Hoelzer D, Mitrou PS, Weidmann E, Chow KU: In the erythroleukemic cell line HEL prostate-apoptosis-response-gene-4 (Par-4) fails to downregulate bcl-2 and to promote apoptosis. Leuk Lymphoma 45 (2004) 1445-1451. Kukoc-Zivojnov N, Puccetti E, Chow KU, Bergmann M, Ruthardt M, Hoelzer D, Mitrou PS, Weidmann E, Boehrer S: Prostate apoptosis response gene-4 (par-4) abrogates the survival function of p185BCR-ABL in hematopoietic cells. Exp Hematol 32 (2004) 649-656. Nowak D, Boehrer S, Brieger A, Kim SZ, Schaaf S, Hoelzer D, Mitrou PS, Weidmann E, Chow KU. Upon drug-induced apoptosis in lymphoma cells X-linked inhibitor of apoptosis (XIAP) translocates from the cytosol to the nucleus. Leuk Lymphoma 45 (2004) 1429-1436. Brieger A, Boehrer S, Schaaf S, Nowak D, Ruthardt M, Kim SZ, Atadja P, Hoelzer D, Mitrou PS, Weidmann E, Chow KU. In BCR-ABL-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone-deacetylase inhibitors. Biochemical Pharmacology 68 (2004) 85-93. Weidmann E, Gramatzki M, Wilhelm M, Mitrou PS: Diagnosis and actual therapy strategies in peripheral Tcell lymphomas – summary of an international meeting. Ann Oncol (South African Exerpts Edidion) 1 (2004) 117-122 (published on request of Ann Oncol). Boehrer S, Nowak D, Schaaf S, Bergmann M, Brieger A, Hoelzer D, Mitrou PS, Weidmann E, Chow KU. In malignant myeloid cells expression of DAXX down-regulates expression of p53 and of the inhibitors of apoptosis proteins. Hematol J 5 (2004) 513-518. Kim SZ, Chow KU, Kukoc-Zivojnov N, Boehrer S, Brieger A, Steimle-Grauer SA, Harder L, Hoelzer D, Mitrou PS, Weidmann E. Expression of ZAP-70 protein correlates with disease stage in chronic lymphatic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status. Leuk Lymphoma 45 (2004) 2037-2045. Bergmann M, Kukoc-Zivojnov N, Chow KU, Trepohl B, Hoelzer D, Weidmann E, Mitrou PS, Boehrer S. Prostate-apoptosis-response-gene-4 sensitizes neoplastic lymphocytes to CD95-induced apoptosis. Ann Hematol 83 (2004) 646-653. Weidmann E: T-Zell-Lymphome. In: Lymphome. Hiddemann W, Dreyling M, Stein H (Eds.) Georg ThiemeVerlag, Stuttgart, New York (2005) 133-156. Boehrer S, Kukoc-Zivojnov, Nowak D, Bergmann M, Baum C, Puccetti E, Weidmann E, Hoelzer D, Mitrou PS, Chow KU. Upon drug-induced apoptosis expression of prostate-apoptosis-response-gene-4 promotes cleavage of caspase-8, bid and mitochondrial release of cytochrome C. Hematology 9 (2004) 425-431. Boehrer S, Nowak D, Kukoc-Zivojnov N, Hochmuth S, Kim SZ, Hoelzer D, Mitrou PS, Weidmann E, Chow KU. Expression of DAXX sensitizes Jurkat T-cells to the apoptosis-inducing effect of chemotherapeutic agents. Pharmacol Res 51 (2005) 367-374. Boehrer S, Nowak D, Hochmuth S, Kim SZ, Trepohl B, Afkir A, Hoelzer D, Mitrou PS, Weidmann E, Chow KU. DAXX overexpression in T-lymphoblastic Jurkat cells enhances caspase-dependent death receptor- and drug-induced apoptosis in distinct ways. Cell Signal 17 (2005) 581-595. Al-Batran SE, Rafiyan MR, Atmaca A, Neumann A, Karbach J, Bender A, Weidmann E, Altmannsberger HM, Knuth A, Jager E. Intratumoral T-cell infiltrates and MHC class 1 expression in patients with stage IV melanoma. Cancer Res 65 (2005) 3937-3941. Chow KU, Nowak D, Kim SZ, Schneider B, Komor M, Boehrer S, Mitrou PS, Hoelzer D, Weidmann E, Hofmann WK. In vivo drug-response in patients with leukemic non-Hodgkin’s lymphomas is associated with in vitro chemosensitivity and gene expression profiling. Pharmacol Res 53 (2006) 49-61. Weidmann E, Mitrou PS. Periphere T-Zell-Lymphome. In: Kompendium Internistische Onkologie; 4. Auflage. Schmoll H-J, Höffken K, Possinger K (Eds.). Springer Verlag (2006) 3048-3065. Willenbrock K, Küppers R, Renné C, Brune V, Eckerle S, Weidmann E, Bräuninger A, Hansmann ML. Common features and differences in the transcriptosome of large cell anaplastic lymphoma and classical Hodgkin’s lymphoma. Haematologica 91 (2006) 596-604. Friedmann I, Atmaca A, Chow KU, Jäger E, Weidmann E. Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer. J Chemother 18 (2006) 415420. Rickerts V, Brodt HR, Schneider B, Weidmann E, Chow KU. Host factors and disease severity in two patients with SARS. Wirtsfaktoren und Erkrankungsschwere in zwei Patienten mit SARS. Laboratoriumsmedizin 30 (2006) 18-22. Al-Batran SE, Kerber A, Atmaca A, Dechow C, Reitsamer E, Schmidt S, Kolassa Y, Neumann A, Weidmann E, Hartmann JT, Jäger E. Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial. Onkologie30 (2007) 2934. Atta J, Chow KU, Weidmann E, Mitrou PS, Hoelzer D, Martin H. Dexa-Beam as salvage therapy in patients with primary refractory aggressive Non-Hodgkin lymphoma. Leuk Lymphoma 48 (2007) 349-356. Weidmann E, Jäger E. Tumor-Escape-Mechanismen. In: Krebsimmuntherapien. Standards und Innovationen. Huber C, Rammensee H-G, Wölfel T, Britten CM (eds.) Deutscher Ärzteverlag Köln (2008) 67-67. Bender A, Karbach J, Neumann A, Jager D, Al-Batran SE, Atmaca A, Weidmann E, Biskamp M, Gnatic S, Pan L, Hoffmann E, Old LJ, Knuth A, Jager E. LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1 expressing cancer. Cancer Immun 7 (2007) 16 Weidmann E. T-Zell-Lymphome. In: NHL Diagnostik und Therapie – State of the Art 2007. Rummel MJ (ed.) Agileum Verlag und Gesundheitsakademie, München (2008) 253-266. Weisel KC, Weidmann E, Anagnostopoulos I, Kanz L, Pezzutto A, Subklewe M. Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma. Int J Hematol 88 (2008) 434-440. Weigert O, Weidmann E, Mueck R, Bentz M, von Schilling C, Rohrberg R, Jentsch-Ulrich K, Hiddemann W, Dreyling M. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long term results of a multicenter observation study. Leuk Lymphoma 50 (2009) 716-722. Weidmann E, Jäger E. Krebserkrankungen mit unbekanntem Primärtumor (CUP). In: Die Onkologie; 2. Auflage. Hiddemann W, Bartram C (eds.) Springer Verlag, Heidelberg (2009) 1778-1790. Karbach J, Gnjatic S, Bender A, Neumann A, Weidmann E, Yuan J, Ferrara CA, Hoffmann E, Old LJ, Altorki NK, Jäger E. Tumor-reactive CD8(+) T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide® ISA-51: Association with survival. Int J Cancer 126 (2010) 909-918. Weidmann E, Hess G, Chow KU, Krause SW, Subklewe M, Kruse J, Soekler M, Kim SZ, Napieralski S, Rech J, Dreyling M, Jäger E, Mitrou PS. A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leuk Lymphoma 51 (2010) 447-455. Weidmann E, Neumann A, Fauth F, Atmaca A, Al-Batran SE, Pauligk C, Jäger E. Phase II study of Bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol 22 (2011) 1839-1844. Hübel K, Fresen MM, Salwender H, Basara N, Beier R, Theurich S, Christopeit M, Bogner C, Galm O, Hartwig R, Heits F, Lordick F, Rösler W, Petersen P, Wehler D, Zander AR, Albert M, Dressler S, Ebinger M, Frickhofen N, Hertenstein B, Kiel M, Liebler S, von Lilienfeld-Toal M, Weidmann E, Weigelt C, Lange F, Kröger N. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use programme. Bone Marrow Transplantation 46 (2011) 1045-1052. Rummel MJ, Niederle N, Maschmeyer G, Banat A, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381 (9873) (2013) 1203-1210. Böll B, Görgen H, Fuchs M, Pluetschow A, Eich HT, Bargetzi MJ, Weidmann E, Junghanß C, Greil R, Scherpe A, Schmalz O, Eichenauer DA, von Tresckow B, Rothe A, Diehl V, Engert A, Borchmann P. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 Trials. J Clin Oncol 31 (2013) 1522-1529. Karbach J, Gnjatic S, Biscamp M, Atmaca A, Weidmann E, Brandt K, Wahle C, Bernhard H, Knuth A, Jäger E. Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic corralates. Cancer Immunol Res 2 (2014) 404-409. Coiffier B, Federico M, Caballero D, Dearden C, Morschhauser F, Jäger U, Trümper L, Zucca E, Gomes da Silva M, Pettengell R, Weidmann E, d‘Amore F, Tilly H, Zinzani PL. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. Cancer Treatment Reviews 40 (2014) 1080-1088. Bergmann L, Maute L, Heil G, Rüssel J. Weidmann E, Köberle D, Fuxius S, Weigang-Köhler K, Aulitzky WE, Wörmann B, Hartung G, Moritz B, Edler L, Burkholder I, Scheulen ME, Richly H. A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer. A study of the CESAR Central European Society for Anticancer Research-EWIV. Eur J Cancer 51 (2015) 27-36. Kirschey S, Flohr T, Wolf HW, Frickhofen N, Gramatzki M, Link H, Basara N, Peter N, Meyer RG, Schmitz N, Weidmann E, Banat A, Schulz A, Kolbe K, Derigs G, Theobald M, Hess G. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study. Br J Haematology 168 (2015) 824-834. Cheson Bruce D, Brugger W, Damaj G, Dreyling M, Kahl B, Kimby E, Ogura M, Weidmann E, Wendtner CM, Zinzani PL. Optimal use of bendamustine in hematologic disorders: treatment recommendations from an international consenus panel – an update. Leuk Lymphoma 23 (2016) 766-752. Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck H-P, Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff Frank, Blau W, Hinke A, Barth J. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle cell lymphomas: a multicentre, randomized, open-label, noninferiority phase 3 trial. Lancet Oncol 17 (2016) 57-66.